Teva looks set to draw a line under its long-running and costly US opioid litigation saga after announcing a nationwide agreement in principle worth $4.35bn, including already concluded agreements, spread over 13 years to resolve most of its cases.
The proposed deal, reached with the working group of states’ attorneys general, counsel for Native American Tribes, and plaintiffs’ lawyers representing the states and subdivisions, includes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?